12 completed, 8 recruiting, 5 unknown, 4 terminated. 20 Phase 1, 10 Phase 2, 3 Not applicable, 3 Phase 3, 2 Early Phase 1.
Follow Automobiles: new trials by email Literature Review of Automobiles trials Research Report on Automobiles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies - CD7-Positive Hematological Malignancies | Not applicable | Not yet recruiting | Donghua Zhang | 28 | 2026-12-31 | 2026-01-16 |
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Dipenkumar Modi | 35 | 2023-10-31 | 2026-07-10 |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 27 | 2023-05-19 | 2026-09-16 |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma PK Blood Collection, CAR, TCR - Nasopharyngeal Carcinoma | Early Phase 1 | Recruiting | Fudan University | 24 | 2022-12-28 | 2026-04-02 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 33 | 2022-04-28 | 2023-02-14 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | John Lister | 30 | 2022-04-19 | 2025-01-13 |
| NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer NKG2D CAR-NK - Refractory Metastatic Colorectal Cancer | Phase 1 | Unknown | Zhejiang University | 38 | 2021-12-10 | 2024-02-12 |
| NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer CAR-T infusion - Refractory Metastatic Colorectal Cancer | Early Phase 1 | Unknown | The Third Affiliated Hospital of Guangzhou Medical University | 9 | 2021-09-13 | 2022-02-21 |
| CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies CD19 Chimeric Antigen Receptor (CAR) T Cells - Relapsed/Refractory B-Cell Malignancies | Phase 1 | Unknown | National Taiwan University Hospital | 12 | 2021-07-01 | 2021-06-29 |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) autologous CD19-directed chimeric antigen receptor (CAR) T-cells - Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL | Phase 1 / Phase 2 | Recruiting | University of Alberta | 63 | 2021-03-03 | 2026-02-09 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 59 | 2021-01-13 | 2023-11-24 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Recruiting | C. Babis Andreadis | 36 | 2020-09-11 | 2026-06-22 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Lymphoma, Non-hodgkins | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2019-12-20 | 2022-02-15 |
| Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel - Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma | Phase 1 | Recruiting | Seattle Children's Hospital | 90 | 2019-12-11 | 2026-04-13 |
| Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) DTG/3TC FDC, CAR - HIV Infections | Phase 3 | Completed | ViiV Healthcare | 493 | 2019-11-11 | 2023-10-19 |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 82 | 2019-06-11 | 2023-11-24 |
Showing 20 of 34. Sign in to see all of them.
Lymphoma, Non-Hodgkin (7) · Lymphoma, Large B-Cell, Diffuse (6) · Recurrence (5) · Brain Neoplasms (4) · Glioma (4) · Lymphoma, Follicular (4) · Central Nervous System Neoplasms (3) · Choroid Plexus Carcinoma (3) · Ependymoma (3) · HIV Infections (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Medulloblastoma (3) · Multiple Myeloma (3)
National Cancer Institute (NCI) (9) · Seattle Children's Hospital (3) · Shanghai Ming Ju Biotechnology Co., Ltd. (3) · ViiV Healthcare (3) · AdventHealth (1) · Bellicum Pharmaceuticals (1) · C. Babis Andreadis (1) · Daniel Landi (1) · Dipenkumar Modi (1) · Donghua Zhang (1) · Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jennifer Crombie, MD (1) · John Lister (1) · National Taiwan University Hospital (1)
United States (25) · China (8) · Canada (4) · Argentina (3) · France (3) · Germany (3) · Italy (3) · Russia (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Brazil (1) · Denmark (1)
James N Kochenderfer, M.D. (6) · Steven A Rosenberg, M.D. (3) · Rebecca Ronsley, MD (2) · Amanda T Sawyer, PhD (1) · Carrie Ho, MD (1) · Christopher R D'Angelo, MD (1) · Daniel Landi, MD (1) · David Ashley, MBBS, FRACP, PhD (1) · Dipenkumar Modi, MD (1) · Dongmei Ji, Doctorate (1) · Dr. Michael P Chu, MD (1) · Jennifer Crombie, MD (1) · John Lister, MD (1) · Juliane Gust, MD, PhD (1)
PMID 29239893, PMID 31307948, PMID 34515338, PMID 14871955, PMID 21212426, PMID 22154591, PMID 22780919, PMID 22826562, PMID 23237707, PMID 23545055, PMID 24190575, PMID 24630534, PMID 25706097, PMID 26017177, PMID 26370838, PMID 26424652, PMID 27412889, PMID 29329591, PMID 29518976, PMID 29812997, PMID 29872570, PMID 29880908, PMID 30207593, PMID 30662890, PMID 31150573, PMID 31178151, PMID 31905218, PMID 32157281, PMID 32272384, PMID 32627860, PMID 33382529, PMID 34253928, PMID 34358493, PMID 35468680, PMID 36053875, PMID 36842849, PMID 37161345, PMID 37640679, PMID 37939262, PMID 38515183, PMID 39015350, PMID 39225890, PMID 39775044, PMID 40811825, PMID 40888120, PMID 41702648, PMID 41798119
2014 (2)